Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 11001 participants.
Also called NCT02406677
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose health services research
- Phase
- Phase 4
- Enrolled
- 11,001 participants
- Registry
-
NCT02406677
-
- Other papers using this trial's data
- Agreement and Accuracy of Medication Persistence Identified by Patient Self-report vs Pharmacy Fill: A Secondary Analysis of the Cluster Randomized ARTEMIS Trial
- Association of a P2Y12 Inhibitor Copayment Reduction Intervention With Persistence and Adherence With Other Secondary Prevention Medications: A Post Hoc Analysis of the ARTEMIS Cluster-Randomized Clinical Trial
- Challenge in Predicting Persistence to P2Y12 Inhibitors: A Perspective From the ARTEMIS Trial
- Copayment Reduction Voucher Utilization and Associations With Medication Persistence and Clinical Outcomes: Findings From the ARTEMIS Trial
- Does the Effectiveness of a Medicine Copay Voucher Vary by Baseline Medication Out-Of-Pocket Expenses? Insights From ARTEMIS
- Effect of Medication Co-payment Vouchers on P2Y12 Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial Infarction: The ARTEMIS Randomized Clinical Trial
- Impact of a Copayment Reduction Intervention on Medication Persistence and Cardiovascular Events in Hospitals With and Without Prior Medication Financial Assistance Programs
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Puerto Rico
- Registry status
- Completed
Technical summary
Registry record NCT02406677. Randomized; no masking; primary purpose health services research. Start 2015-06-05 (actual); primary completion 2017-10-23 (actual). Results posted on 2019-10-01.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study
- Acronym
- ARTEMIS
- Condition
- Cost Sharing, Acute Coronary Syndrome
- Intervention (Other)
- Study voucher card
- Lead sponsor
- AstraZeneca
- Collaborator
- Duke Clinical Research Institute
Record details
- Record id
cardio:ct-nct02406677- Content hash
a13c94116c95add4bab2d9fc9ed6aae0a9ecfcfc85e2e7cb9765aca201a0a493